AU2020298758A1 - Therapeutic interactions of leucomethylthioninium - Google Patents

Therapeutic interactions of leucomethylthioninium Download PDF

Info

Publication number
AU2020298758A1
AU2020298758A1 AU2020298758A AU2020298758A AU2020298758A1 AU 2020298758 A1 AU2020298758 A1 AU 2020298758A1 AU 2020298758 A AU2020298758 A AU 2020298758A AU 2020298758 A AU2020298758 A AU 2020298758A AU 2020298758 A1 AU2020298758 A1 AU 2020298758A1
Authority
AU
Australia
Prior art keywords
treatment
compound
therapeutic
subject
disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2020298758A
Other languages
English (en)
Inventor
Jochen Klein
Valeria MELIS
Grazyna NIEWIADOMSKA
Gernot Riedel
Karima SCHWAB
Marta STECZKOWSKA
Claude Michel Wischik
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Taurx Therapeutics Management Ltd
Original Assignee
Taurx Therapeutics Management Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Taurx Therapeutics Management Ltd filed Critical Taurx Therapeutics Management Ltd
Publication of AU2020298758A1 publication Critical patent/AU2020298758A1/en
Assigned to TauRx Therapeutics Management Ltd reassignment TauRx Therapeutics Management Ltd Request for Assignment Assignors: WISTA LABORATORIES LTD.
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/48—Other medical applications
    • A61B5/4848—Monitoring or testing the effects of treatment, e.g. of medication
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medical Informatics (AREA)
  • Molecular Biology (AREA)
  • Surgery (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Rheumatology (AREA)
  • Toxicology (AREA)
  • Urology & Nephrology (AREA)
  • Steroid Compounds (AREA)
AU2020298758A 2019-07-01 2020-06-30 Therapeutic interactions of leucomethylthioninium Pending AU2020298758A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1909493.7A GB201909493D0 (en) 2019-07-01 2019-07-01 Therapeutic interactions
GB1909493.7 2019-07-01
PCT/EP2020/068422 WO2021001380A1 (en) 2019-07-01 2020-06-30 Therapeutic interactions of leucomethylthioninium

Publications (1)

Publication Number Publication Date
AU2020298758A1 true AU2020298758A1 (en) 2022-02-24

Family

ID=67540109

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2020298758A Pending AU2020298758A1 (en) 2019-07-01 2020-06-30 Therapeutic interactions of leucomethylthioninium

Country Status (12)

Country Link
US (1) US20230031369A1 (https=)
EP (1) EP3989954A1 (https=)
JP (1) JP7638915B2 (https=)
KR (1) KR20220027203A (https=)
CN (1) CN114126622A (https=)
AU (1) AU2020298758A1 (https=)
BR (1) BR112021025256A2 (https=)
CA (1) CA3143790A1 (https=)
GB (1) GB201909493D0 (https=)
IL (1) IL289338B1 (https=)
MX (1) MX2021015292A (https=)
WO (1) WO2021001380A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7073330B2 (ja) 2016-07-25 2022-05-23 ウィスタ ラボラトリーズ リミテッド ジアミノフェノチアジンの投与及び投与量
FI4385512T3 (fi) 2018-07-26 2026-01-12 Taurx Therapeutics Man Ltd Diaminofenotiatsiinien optimoitu annostus populaatioille

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0100119D0 (en) 2001-01-03 2001-02-14 Univ Aberdeen Materials and methods relating to protein aggregation in neurodegenerative disease
GB0106953D0 (en) 2001-03-20 2001-05-09 Univ Aberdeen Neufofibrillary labels
ES2349322T7 (es) 2006-03-29 2019-10-17 Wista Lab Ltd Sales de 3,7-diamino-10H-fenotiazina y su utilización
AU2008265045B2 (en) 2007-06-19 2014-02-27 Taurx Therapeutics Management Ltd. Phenothiazine compounds for treating Mild Cognitive Impairment
CA2701075C (en) 2007-10-03 2019-02-12 Wista Laboratories Ltd. Therapeutic use of diaminophenothiazines.
EP2227766A2 (en) 2007-11-05 2010-09-15 Wista Laboratories Ltd. Systems for clinical trials
JP5898701B2 (ja) 2011-02-11 2016-04-13 ウィスタ ラボラトリーズ リミテッド フェノチアジンジアミニウム塩およびそれらの使用
JP7073330B2 (ja) * 2016-07-25 2022-05-23 ウィスタ ラボラトリーズ リミテッド ジアミノフェノチアジンの投与及び投与量
GB201614834D0 (en) * 2016-09-01 2016-10-19 Wista Lab Ltd Treatment of dementia
FI4385512T3 (fi) * 2018-07-26 2026-01-12 Taurx Therapeutics Man Ltd Diaminofenotiatsiinien optimoitu annostus populaatioille

Also Published As

Publication number Publication date
EP3989954A1 (en) 2022-05-04
MX2021015292A (es) 2022-01-18
KR20220027203A (ko) 2022-03-07
JP7638915B2 (ja) 2025-03-04
IL289338A (en) 2022-02-01
IL289338B1 (en) 2026-03-01
CN114126622A (zh) 2022-03-01
WO2021001380A1 (en) 2021-01-07
JP2022538642A (ja) 2022-09-05
GB201909493D0 (en) 2019-08-14
BR112021025256A2 (pt) 2022-01-25
US20230031369A1 (en) 2023-02-02
CA3143790A1 (en) 2021-01-07

Similar Documents

Publication Publication Date Title
JP7686581B2 (ja) 認知機能の向上薬としてのメチルチオニニウム
EP2954932B1 (en) Therapeutic use of diaminophenothiazines
KR102559354B1 (ko) 치매 치료
EP2167095B1 (en) Phenothiazine compounds for treating mild cognitive impairment
JP2017137298A (ja) ラキニモドおよびフィンゴリモドを組み合わせた多発性硬化症の治療
US20200113882A1 (en) Use of 4-Aminopyridine to Improve Neuro-Cognitive and/or Neuro-Psychiatric Impairment in Patients with Demyelinating and Other Nervous System Conditions
CA3120856A1 (en) Gaboxadol for reducing risk of suicide and rapid relief of depression
US20220370470A1 (en) Methylthioninium for use in the treatment of synaptopathies
US20230031369A1 (en) Therapeutic interactions of leucomethylthioninium
RU2834773C2 (ru) Терапевтические взаимодействия лейкометилтиониния
RU2824584C2 (ru) Метилтиониний в качестве усилителя когнитивной функции
Ligsay et al. Overview of targeted double-blind, placebo-controlled clinical trials in fragile X syndrome
KR20160085757A (ko) 다발성 경화증의 치료를 위한 라퀴니모드 병용 치료
WORKS Current
HK1211889B (en) Therapeutic use of diaminophenothiazines

Legal Events

Date Code Title Description
PC1 Assignment before grant (sect. 113)

Owner name: TAURX THERAPEUTICS MANAGEMENT LTD

Free format text: FORMER APPLICANT(S): WISTA LABORATORIES LTD.